LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Valerie W, McClain" <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Fri, 5 Dec 2003 15:43:12 EST
Content-Type:
text/plain
Parts/Attachments:
text/plain (47 lines)
Here's another patent.  The is called "nutritional formulation containing
prebiotic substances," invented by Jeffrey Wilson and assigned to Wyeth (filed in
2001).  Another human milk component "borrowed" for the infant formula
company to use.
Valerie W. McClain, IBCLC

http://www.uspto.gov/patft/index.html
patent # 6630452

"Sialyllactoses are oligosaccharides which occur naturally in human milk as
well as in milk of other mammals. However, sialyllactoses are present at
noticeably higher concentrations in human milk compared to other mammalian species.

The two primary species of sialyllactose are 3'-sialyllactose and
6'-sialyllactose. These species occur naturally in human milk at a relative ratio of 1:3
(3':6'). Sialyllactose is known to have anti-adhesive properties for specific
pathogenic bacteria. For example, it has been suggested that sialyllactose
acts to inhibit cholera toxin (see, Idota et al, "Inhibition of Cholera Toxin by
Human Milk Fractions and Sialyllactose," Biosci. Biotech. Biochem. 59:417-419)
and Helicobacter pylori (see, Simon et al, "Inhibition of Helicobacter pylori
Binding to Gastrointestinal Epithelial Cells by Sialic Acid-Containing
Oligosaccharides," Infection and Immunity, 750-757, (1997)). In light of its
antiadhesive properties, sialyllactose has been used to treat a number of medical
conditions. For example, U.S. Pat. Nos. 5,514,660 and 5,753,630, describe the use
of sialyllactose in the treatment and inhibition of duodenal ulcers. U.S.
Pat. No. 5,883,079 describes the use of sialyllactose to inhibit H. pylori
infection in mammalian tissue.

However, the use of two prebiotic substances, specifically, oligofructose and
sialyllactose, in combination has heretofore not been described. Accordingly,
it can be seen that there is a need for such a combination."




             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2